|
1
|
Mercadante S, Gebbia V, Marrazzo A and
Filosto S: Anaemia in cancer: Pathophysiology and treatment. Cancer
Treat Rev. 26:303–311. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Henry DH: Supplemental Iron: A key to
optimizing the response of cancer-related anemia to rHuEPO?
Oncologist. 3:275–278. 1998.PubMed/NCBI
|
|
3
|
Kasper C, Terhaar A, Fosså A, Welt A,
Seeber S and Nowrousian MR: Recombinant human erythropoietin in the
treatment of cancer-related anaemia. Eur J Haematol. 58:251–216.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pronzato P: Cancer-related anaemia
management in the 21st century. Cancer Treat Rev. 32 Suppl 2:S1–S3.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ludwig H, Evstatiev R, Kornek G, Aapro M,
Bauernhofer T, Buxhofer-Ausch V, Fridrik M, Geissler D, Geissler K,
Gisslinger H, et al: Iron metabolism and iron supplementation in
cancer patients. Wien Klin Wochenschr. 127:907–919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Littlewood TJ: Erythropoietin for the
treatment of anemia associated with hematological malignancy.
Hematol Oncol. 19:19–30. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glaspy J: The impact of epoetin alfa on
quality of life during cancer chemotherapy: A fresh look at an old
problem. Semin Hematol. 34 3 Suppl 2:S20–S26. 1997.
|
|
8
|
Brandberg Y: Assessing the impact of
cancer-related anaemia on quality of life and the role of rHuEPO.
Med Oncol. 17(Suppl 1): S23–S31. 2000.PubMed/NCBI
|
|
9
|
Rice L, Alfrey CP, Driscoll T, Whitley CE,
Hachey DL and Suki W: Neocytolysis contributes to the anemia of
renal disease. Am J Kidney Dis. 33:59–62. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leng HM, Albrecht CF, Kidson SH and Folb
PI: Erythropoietin production in anemia associated with
experimental cancer. Exp Hematol. 27:806–810. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feelders RA, Vreugdenhil G, Eggermont AM,
Kuiper-Kramer PA, van Eijk HG and Swaak AJ: Regulation of iron
metabolism in the acute-phase response: Interferon gamma and tumour
necrosis factor alpha induce hypoferraemia, ferritin production and
a decrease in circulating transferrin receptors in cancer patients.
Eur J Clin Invest. 28:520–527. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung IJ, Dai C and Krantz SB: Stem cell
factor increases the expression of FLIP that inhibits IFNgamma
-induced apoptosis in human erythroid progenitor cells. Blood.
101:1324–1328. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rodriguez S and ánchez CA: Recommendation
of the scientific societies on the treatment of anaemia in cancer
patients. Clin Transl Oncol. 9:582–589. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garcia JM Jurado, Sánchez E Torres,
Hidalgo D Olmos and Alba Conejo E: Erythropoietin pharmacology.
Clin Transl Oncol. 9:715–722. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ahlqvist-Rastad J, Albertsson M, Bergh J,
Birgegård G, Johansson P, Jonsson B, Kjellen E, Påhlman S,
Zackrisson B and Osterborg A: Erythropoietin therapy and cancer
related anaemia: Updated Swedish recommendations. Med Oncol.
24:267–272. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deeks JJ: Issues in the selection of a
summary statistic for meta-analysis of clinical trials with binary
outcomes. Stat Med. 21:1575–1600. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Higgins J and Green S: Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration; 2011, simplewww.cochrane-handbook.orgOctober 1–2011
|
|
18
|
Walter SD and Yao X: Effect sizes can be
calculated for studies reporting ranges for outcome variables in
systematic reviews. J Clin Epidemiol. 60:849–852. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Higgins JP and Thompson SG: Quantifying
heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Henke M, Laszig R, Rübe C, Schäfer U,
Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and
Frommhold H: Erythropoietin to treat head and neck cancer patients
with anaemia undergoing radiotherapy: Randomised, double-blind,
placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Copas J and Shi JQ: Meta-analysis, funnel
plots and sensitivity analysis. Biostatistics. 1:247–262. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kettelhack C, Hönes C, Messinger D and
Schlag PM: Randomized multicentre trial of the influence of
recombinant human erythropoietin on intraoperative and
postoperative transfusion need in anaemic patients undergoing right
hemicolectomy for carcinoma. Br J Surg. 85:63–67. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Scott SN, Boeve TJ, McCulloch TM,
Fitzpatrick KA and Karnell LH: The effects of epoetin alfa on
transfusion requirements in head and neck cancer patients: A
prospective, randomized, placebo-controlled study. Laryngoscope.
112:1221–1229. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kosmadakis N, Messaris E, Maris A,
Katsaragakis S, Leandros E, Konstadoulakis MM and Androulakis G:
Perioperative erythropoietin administration in patients with
gastrointestinal tract cancer: Prospective randomized double-blind
study. Ann Surg. 237:417–421. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Christodoulakis M and Tsiftsis DD:
Hellenic Surgical Oncology Perioperative EPO Study Group:
Preoperative epoetin alfa in colorectal surgery: A randomized,
controlled study. Ann Surg Oncol. 12:718–725. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mystakidou K, Kalaidopoulou O, Katsouda E,
Parpa E, Kouskouni E, Chondros C, Tsiatas ML and Vlahos L:
Evaluation of epoetin supplemented with oral iron in patients with
solid malignancies and chronic anemia not receiving anticancer
treatment. Anticancer Res. 25:3495–3500. 2005.PubMed/NCBI
|
|
27
|
Lacson E Jr, Ofsthun N and Lazarus JM:
Effect of variability in anemia management on hemoglobin outcomes
in ESRD. Am J Kidney Dis. 41:111–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rainville N, Jachimowicz E and Wojchowski
DM: Targeting EPO and EPO receptor pathways in anemia and
dysregulated erythropoiesis. Expert Opin Ther Targets. 20:287–301.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Singh PK, Devasahayam M and Devi S:
Expression of GPI anchored human recombinant erythropoietin in CHO
cells is devoid ofglycosylation heterogeneity. Indian J Exp Biol.
53:195–201. 2015.PubMed/NCBI
|
|
30
|
Aapro M: Emerging topics in anaemia and
cancer. Ann Oncol. 23 Suppl 10:x289–x293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rice L and Alfrey CP: The negative
regulation of red cell mass by neocytolysis: Physiologic and
pathophysiologic manifestations. Cell Physiol Biochem. 15:245–250.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Means RT Jr and Krantz SB: Progress in
understanding the pathogenesis of the anemia of chronic disease.
Blood. 80:1639–1647. 1992.PubMed/NCBI
|
|
33
|
Borstlap WA, Buskens CJ, Tytgat KM,
Tuynman JB, Consten EC, Tolboom RC, Heuff G, van Geloven AA, van
Wagensveld BA, Wientjes CA, et al: Erratum to: Multicentre
randomized controlled trial comparing ferric (III)carboxymaltose
infusion with oral iron supplementation in the treatment of
preoperative anaemia in colorectal cancer patients. BMC Surg.
15:1102015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Laï-Tiong F, Brami C, Dubroeucq O, Scotté
F, Curé H and Jovenin N: Management of anemia and iron deficiency
in a cancer center in France. Support Care Cancer. 24:1091–1096.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Braga M, Gianotti L, Vignali A, Gentilini
O, Servida P, Bordignon C and Di Carlo V: Evaluation of recombinant
human erythropoietin to facilitate autologous blood donation before
surgery in anaemic patients with cancer of the gastrointestinal
tract. Br J Surg. 82:1637–1640. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jackson D, White IR, Mason D and Sutton S:
A general method for handling missing binary outcome data in
randomized controlled trials. Addiction. 109:1986–1993. 2014.
View Article : Google Scholar : PubMed/NCBI
|
